Panacea Biotec Limited

NSE:PANACEABIO.NS

415.9 (INR) • At close January 15, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q1
Revenue 1,473.51,157.21,364.61,5051,430.21,291.91,289.31,1521,051.21,1071,387.231,558.82,321.71,324.51,611.091,417.61,820.21,327.61,184.861,677.41,251.81,257.81,223.461,103.81,203.3992.8
Cost of Revenue 431.9879.5969.91,140.8581.9548.6574.8477.8364.51,109.51,069.07465.91,038.8426.3827.83425.1638394.4573.34522.8368.9280.71,093.59253.4435.4244.7
Gross Profit 1,041.6277.7394.7364.2848.3743.3714.5674.2686.7-2.5318.161,092.91,282.9898.2783.26992.51,182.2933.2611.521,154.6882.9977.1129.87850.4767.9748.1
Gross Profit Ratio 0.7070.240.2890.2420.5930.5750.5540.5850.653-0.0020.2290.7010.5530.6780.4860.70.6490.7030.5160.6880.7050.7770.1060.770.6380.754
Reseach & Development Expenses 000000328.2000358.03000390.17000107.08000255.83000
General & Administrative Expenses 000000247.49000471.63000456.96000396.65000393.75000
Selling & Marketing Expenses 000000218.21000220.05000183.74000209.78000136.44000
SG&A 0504.9543.2456.8508.7359.7465.7440.4406.8320.8691.68456.7457.3469.6640.7391.7375.2351606.43367354.8321530.19315.3378.8395.9
Other Expenses 1,041.6740108.156.832.360.8150.6139.4104.5122.1-35.2316.620.332.3-30.6418.92011.9-108.4332.334.550.3-58.8532.917.129.7
Operating Expenses 1,041.6504.9543.2456.8977941.21,128.5595.1824896.1687.791,079.81,331.71,024.3832.86954.1915.9821.1401.52893.51,053.7856.9385.681,114.31,001.91,042.1
Operating Income 0-227.2-148.5-92.6-96.4-137.1-263.4384-32.8-776.5-391.5829.7-28.5-126.1-49.638.4266.3112.1133.99261.1-170.8120.2-255.81-263.9-234-294
Operating Income Ratio 0-0.196-0.109-0.062-0.067-0.106-0.2040.333-0.031-0.701-0.2820.019-0.012-0.095-0.0310.0270.1460.0840.1130.156-0.1360.096-0.209-0.239-0.194-0.296
Total Other Income Expenses Net 47.656.771.98-16.5-77.8-253.3445.55-129.6-135.3-188.316,479.54-504.7-481.3-446.6-476.96-438.5-454.4-439.8-802.4-439.4-533.9-3572,180.54174.2-751.1-663.9
Income Before Tax 47.6-170.5-21.2-16.5-77.8130.3182.1224.4233.1-511.616,082.49-491.6-530.1-572.7-526.56-400.1-188.1-327.7-592.4-178.3-704.7-236.81,872.65-89.7-985.1-311.7
Income Before Tax Ratio 0.032-0.147-0.016-0.011-0.0540.1010.1410.1950.222-0.46211.593-0.315-0.228-0.432-0.327-0.282-0.103-0.247-0.5-0.106-0.563-0.1881.531-0.081-0.819-0.314
Income Tax Expense 0.5-11.7-1.35.55.120.5308.930.776.149.83,707.850.400.814.870.40.93.491.523.123.528.325.9749-24.526.6
Net Income 48-158-14.3-22.8-82.9109.8-126.8193.7157-561.412,374.45-492-530.1-573.5-541.86-400.5-193.3-341.3-696.77-213.2-750-282.71,859.27-159.4-970-352.6
Net Income Ratio 0.033-0.137-0.01-0.015-0.0580.085-0.0980.1680.149-0.5078.92-0.316-0.228-0.433-0.336-0.283-0.106-0.257-0.588-0.127-0.599-0.2251.52-0.144-0.806-0.355
EPS 0.77-2.59-0.23-0.37-1.351.78-2.073.162.56-9.17202.03-8.03-8.65-9.36-8.85-6.54-3.16-5.58-11.38-3.48-12.25-4.6230.39-2.6-15.83-5.75
EPS Diluted 0.77-2.59-0.23-0.37-1.351.78-2.073.162.56-9.17202.02-8.03-8.65-9.36-8.85-6.54-3.16-5.58-11.38-3.48-12.25-4.6230.39-2.6-15.83-5.75
EBITDA 144.2-74.575.183.124.4235.1287.7330.7343.8-398.616,500.7135.280.516.858.4170.4400.1237.3-48.9401.4-179.1284.8-663.8255.7-556.4-127.4
EBITDA Ratio 0.098-0.064-0.044-0.001-0.002-0.0330.0730.190.063-0.61111.8870.0870.0350.0130.0340.120.220.1790.1980.239-0.020.226-0.5430.232-0.068-0.128